| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15da6f5122890450a69ce50b149e9a67 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2010-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b249703b36f33a2c430a7ebdaa3ea0fa |
| publicationDate |
2011-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011129507-A1 |
| titleOfInvention |
Controlled release formulations exhibiting an ascending rate of release |
| abstract |
A sustained release dosage form is comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides an ascending rate of release of the pharmaceutically active agent for at least about 4 hours. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents. When additional pharmaceutically active agents are present, the agents are released from the dosage form at rates that are proportional to the respective weights of each active agent in the dosage form. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8668929-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9198861-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8658631-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8372432-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9050335-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8377453-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8858963-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8394408-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010015222-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8597681-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8741885-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011052685-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9433582-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010196474-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9539328-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9468636-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9629837-B2 |
| priorityDate |
2003-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |